Boston Scientific has recently announced its acquisition of Intera Oncology, a manufacturer specializing in treatments for liver tumors, particularly those caused by metastatic colorectal cancer. Intera is known for its Intera 3000 hepatic artery infusion pump and chemotherapy drug floxuridine, both of which have received FDA approval.
This acquisition marks another strategic move by Boston Scientific in expanding its cancer treatment portfolio. The company has been actively involved in mergers and acquisitions this year, including the successful completion of a $3.7 billion acquisition of Axonics and the purchase of Silk Road Medical for $1.28 billion. The Intera 3000 pump is a small, implantable device designed to deliver continuous chemotherapy directly to liver tumors through the hepatic artery.
Colorectal cancer affects a significant number of individuals in the U.S., with approximately 1.4 million cases reported in 2021. A substantial portion of these cases involve the spread of cancer to the liver, highlighting the importance of effective treatment options. Peter Pattison, Boston Scientific’s president of interventional oncology and embolization, emphasized the significance of the acquisition in offering comprehensive solutions for both primary and metastatic liver cancer.
The Intera 3000 pump is currently indicated for use in patients with unresectable colorectal masses in the liver, both pre and post-surgery. Intera is actively engaged in research to explore the application of this technology in various stages of cancer treatment. Boston Scientific anticipates that this acquisition may impact its 2025 earnings per share due to acquisition-related expenses.
The acquisition of Intera Oncology underscores Boston Scientific’s commitment to advancing cancer treatment options and addressing the critical needs of patients with liver tumors. This strategic move aligns with the company’s goal of providing innovative and effective solutions to improve patient outcomes and quality of life. As the oncology landscape continues to evolve, collaborations and acquisitions such as this play a vital role in driving progress and innovation in cancer care.
